This Medudy course is a video tutorial for physicians on the topic of "Discontinuation of IMM or TNF antagonists in IBD in remission". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
The discontinuation of immunomodulators (IMM) or tumor necrosis factor (TNF) antagonists in patients with inflammatory bowel disease (IBD) in remission under combination therapy is generally attractive. In this systematic review, the efficacy and safety of discontinuing IMM and TNF antagonists in patients with IBD in sustained remission under combination therapy were investigated.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
